Medimetriks Pharmaceuticals, Inc.

Pelthos Therapeutics Acquires Xepi for Antibiotic-Resistant Impetigo Treatment and Secures $18 Million Financing

- Pelthos Therapeutics acquired U.S. commercialization rights to Xepi (ozenoxacin) cream, the first new impetigo treatment approved in over 10 years, addressing critical antibiotic resistance issues. - The FDA-approved topical antimicrobial targets impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, affecting approximately 3 million Americans annually, primarily children ages 2-5. - The company secured $18 million in convertible notes financing to support Xepi's re-launch in late 2026 and accelerate commercialization of its molluscum contagiosum treatment ZELSUVMI. - Xepi represents a significant therapeutic advancement as one of few treatments effective against both methicillin-resistant and mupirocin-resistant Staphylococcus aureus infections.